Pharmacokinetics and cardiovascular effect of etoricoxib in the absence or presence of St. John's Wort in rats

Arzneimittel-Forschung/Drug Research

Volumn 62, Issue 7, 2012, Pages 313-318

  Radwan, M A ^a   Abdel Baky, Nayira A ^b   Zaghloul, I ^b   Aboul Enein, H Y ^c  

^a PRINCESS NOURAH BINT ABDULRAHMAN UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

blood pressure; etoricoxib; pharmacokinetics; rats; St. John's Wort

Indexed keywords

ETORICOXIB; HYPERICUM PERFORATUM EXTRACT;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; STEADY STATE;

EID: 84864115311     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0032-1309043     Document Type: Article

References (53)

1. Katz N. Coxibs: Evolving role in pain management. Seminars in Arthritis and Rheumatism: 2002; 32 3 01 15 24 (Pubitemid 36055617)
2. Matsumoto A K, Cavanaugh P F Jr. Etoricoxib. Drugs of Today: 2004; 40 395 414 (Pubitemid 38858907)
3. Hawley C. COX-2 inhibitors. Lancet: 1999; 353 307
4. Simmons D L, Botting R M, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev: 2004; 56 387 437 (Pubitemid 39096597)
5. Prasit P, Wang Z, Brideau C et al. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4-methylsulfonylphenyl) 3-phenyl-2(5H)-furanone], an orally active cyclooxygenase -2-inhibitor. Bioorg Med Chem Lett: 1999; 9 1773 1778
6. Chan C C, Boyce S, Brideau C et al. Rofecoxib [Vioxx, MK-0966; 4-(4-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. Pharmacol Exp Ther: 1999; 290 551 560 (Pubitemid 29344546)
7. Penning T D, Talley J J, Bertenshaw S R et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, celecoxib). J Med Chem: 1997; 40 1347 1365 (Pubitemid 27198082)
8. Chauret N, Yergey J A, Brideau C et al. In Vitro Metabolism Considerations, Including Activity Testing of Metabolites, in the Discovery and Selection of the COX-2 Inhibitor Etoricoxib (MK-0663). Bioorg Med Chem Lett: 2001; 11 1059 1062 (Pubitemid 32319980)
9. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med: 2000; 343 1520 1528
10. Bertagnolli M M, Eagle C J, Zauber A G et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med: 2006; 355 873 884 (Pubitemid 44315980)
11. Ott E, Nussmeier N A, Duke P C et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg: 2003; 125 1481 1492 (Pubitemid 36759251)
12. Solomon S D, McMurray J J, Pfeffer M A et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med: 2005; 352 1071 1080 (Pubitemid 40365348)
13. Nussmeier N A, Whelton A A, Brown M T et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med: 2005; 352 1081 1091 (Pubitemid 40365349)
14. Bresalier R S, Sandler R S, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med: 2005; 352 1092 1102 (Pubitemid 40365350)
15. Kearney P M, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ: 2006; 332 1302 1308
16. Catella-Lawson F, McAdam B, Morrison B W et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp The: 1999; 289 735 741 (Pubitemid 29191226)
17. McAdam B F, Catella-Lawson F, Mardini I A et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sc U.S.A: 1999; 96 272 277 (Pubitemid 29036089)
18. Brater D C, Anderson S A, Brown-Cartwright D et al. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus of cyclooxygenase-2- selective inhibition. Am J Med: 1999; 107 565 570
19. Riendeau D, Percival M D, Brideau C et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharm Exp Ther: 2001; 296 558 566 (Pubitemid 32112486)
20. Dallob A, Hawkey C J, Greenberg H et al. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol: 2003; 43 573 585 (Pubitemid 36613116)
21. Takemoto J K, Reynolds J K, Remsberg C M et al. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet: 2008; 47 703 720
22. Cochrane D J, Jarvis B, Keating G M. Etoricoxib. Drugs: 2002; 62 2637 2651 (Pubitemid 36098992)
23. Agrawal N G, Porras A G, Matthews C Z et al. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J Clin Pharmacol: 2001; 41 1106 1110 (Pubitemid 32880139)
24. Schwartz J I, Thach C, Lasseter K C et al. Effects of Etoricoxib and Comparator Nonsteroidal Anti-Inflammatory Drugs on Urinary Sodium Excretion, Blood Pressure, and Other Renal Function Indicators in Elderly Subjects Consuming a Controlled Sodium Diet. J Clin Pharmacol: 2007; 47 1521 1531 (Pubitemid 350115301)
25. Cannon C P, Curtis S P, FitzGerald G A et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet: 2006; 368 1771 1781 (Pubitemid 44739003)
26. Wheaton A G, Blanck H M, Gizlice Z et al. Medicinal herb use in a population-based survey of adults: prevalence and frequency of use, reasons for use, and use among their children. Ann Epidemiol: 2005; 15 678 685 (Pubitemid 41266972)
27. McNaughton S A, Mishra G D, Paul A A et al. Supplement use is associated with health status and health related behaviors in the 1946 British birth cohort. J Nutr: 2005; 135 1782 1789 (Pubitemid 40980734)
28. Peng C C, Glassman P A, Trilli L E et al. Incidence and severity of potential drug-dietary supplement interactions in primary care patients: an exploratory study of 2 outpatient practices. Arch Intern Med: 2004; 164 630 636 (Pubitemid 38392977)
29. Bailey D G, Dresser G K. Natural products and adverse drug interactions. CMAJ: 2004; 170 1531 1532 (Pubitemid 38686180)
30. Morrow J D, Edeki T I, El Mouelhi M et al. American Society for Clinical Pharmacology and Therapeutics position statement on dietary supplement safety and regulation. Clin Pharmacol Ther: 2005; 77 113 122 (Pubitemid 40269126)
31. Linde K, Ramirez G, Mulrow C D et al. John's Wort for depression - an overview and meta-analysis of randomized clinical trials. BMJ: 1996; 313 253 258 (Pubitemid 26254730)
32. Gaster B, Holroyd J. St John's Wort for depression. Arch Intern Med: 2000; 160 152 156
33. Morris C A, Avorn J. Internet Marketing Herbal Products. JAMA: 2003; 290 1505 1509
34. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol: 2001; 52 587 595
35. Dresser G K, Schwarz U I, Wilkinson G R et al. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther: 2003; 73 41 50 (Pubitemid 36158485)
36. Markowitz J S, Donovan J L, DeVane C L et al. Effect of St John's Wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA: 2003; 290 1500 1504 (Pubitemid 37430406)
37. Kawaguchi A, Ohmori M, Tsuruoka S et al. Drug interaction between St John's wort and quazepam. Br J Clin Pharmacol: 2004; 58 403 410 (Pubitemid 39312464)
38. Nebel A, Schneider B J, Baker R K et al. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother: 1999; 33 502 (Pubitemid 29215819)
39. Murakami Y, Tanaka T, Murakami H et al. Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A. Br J Clin Pharmacol: 2006; 61 671 676 (Pubitemid 43794792)
40. Radwan M A, Zaghloul I Y, Abd Elbaky N A. Stability indicating high performance liquid chromatographic assay for the pharmacokinetics of Cyclooxygenase (COX-2) inhibitor etoricoxib in rats. Afr J Pharm Pharmacol: 2009; 3 339 346
41. nd Ed. New York Marcel Dekker Inc.: 1982
42. Solomon D H, Schneeweiss S, Levin R et al. The relationship between COX-2 specific inhibitors and hypertension. Hypertension: 2004; 44 140 145 (Pubitemid 39014229)
43. Dürr D, Stieger B, Kullak-Ublick G A et al. John's Wort induces intestinal Pglycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther: 2000; 68 598 604 (Pubitemid 32059985)
44. Ruschitzka F, Meier P J, Turina M et al. Acute heart transplant rejection due to Saint John's wort. Lancet: 2000; 355 548 549 (Pubitemid 30088678)
45. Piscitelli S C, Burstein A H, Chaitt D et al. Indinavir concentrations and St John's wort. Lancet: 2000; 355 547 548 (Pubitemid 30088677)
46. Johne A, Brockmöller J, Bauer S et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther: 1999; 66 338 345 (Pubitemid 29494126)
47. Frye R F, Fitzgerald S M, Lagattuta T F et al. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther: 2004; 76 323 329 (Pubitemid 39313122)
48. Schwarz U I, Büschel B, Kirch W. Unwanted pregnancy on selfmedication with St John's wort despite hormonal contraception. Br J Clin Pharmacol: 2003; 55 112 113 (Pubitemid 36110847)
49. Mai I, Störmer E, Bauer S et al. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant: 2003; 18 819 822 (Pubitemid 36432268)
50. Bennett W M, Henrich W L, Stoff J S. The renal effects of nonsteroidal anti-inflammatory drugs: Summary and recommendations. Am J Kidney Dis: 1996; 28 01 556 562
51. Whelton A, Hamilton C W. Nonsteroidal anti-inflammatory drugs: Effects on kidney function. J Clin Pharmacol: 1991; 31 588 598
52. Heerdink E R, Leufkens H G, Herings R M et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med: 1998; 158 1108 1112 (Pubitemid 28242315)
53. De Leeuw P W. Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. Drugs: 1996; 51 179 187